Description: ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop product candidates that address high unmet medical needs in the areas of renal and inflammatory diseases. ZyVersa's development pipeline includes phase 2a ready VAR 200, a cholesterol efflux mediator for treatment of rare kidney disease, focal segmental glomerulosclerosis. ZyVersa believes VAR 200 has potential to treat other glomerular diseases, including Alport syndrome and diabetic kidney disease. ZyVersa's development pipeline also includes IC 100, a novel inflammasome ASC inhibitor being developed to treat a multitude of inflammatory diseases.
Home Page: www.zyversa.com
ZVSA Technical Analysis
2200 North Commerce Parkway
Weston,
FL
33326
United States
Phone:
646 414 6965
Officers
| Name | Title |
|---|---|
| Mr. Stephen C. Glover | Co-Founder, CEO & Chairman |
| Mr. Peter Wolfe | Sr. VP of Fin. & Admin. |
| Mr. Nicholas A. LaBella Jr., MS, RPh. | Chief Scientific Officer and Sr. VP of R&D |
| Ms. Melda Uzbil O'connell | Sr. VP of Corp. Devel. |
| Ms. Karen A. Cashmere | Chief Commercial Officer |
| Dr. Pablo A. Guzman M.D. | Chief Medical Officer & Member of Scientific Advisory Board |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2022-12-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 6 |